Latest News

At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug

The Food and Drug Administration on Friday approved the first gene therapy for a type of spinal muscular atrophy, a lifesaving treatment for infants that will also be the most expensive drug in the world.

Known as Zolgensma, the gene therapy treats children under 2 years of age with spinal muscular atrophy, an inherited neuromuscular disease that causes progressive loss of muscle function. The most severe form of SMA causes infants to die or rely on permanent breathing support by the age of 2. The disease is caused by a defect in a gene that makes SMN, a protein necessary for the survival of motor neurons. Zolgensma uses a re-engineered virus to deliver a functional copy of the defective gene so that SMN protein can be produced.

Read the rest…

Source link




Related posts

EMA urged to release full clinical trial data upon authorizing Covid-19 treatments

Newsemia

Molecular Sensor to Detect if Cancer Drug is Working

Newsemia

SORT OUT IX: Biolimus-eluting stent noninferior to SES

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy